IMVT
Price
$26.73
Change
-$0.78 (-2.84%)
Updated
Oct 16 closing price
Capitalization
6.92B
32 days until earnings call
Intraday BUY SELL Signals
KURA
Price
$9.08
Change
-$0.62 (-6.39%)
Updated
Oct 16 closing price
Capitalization
943.87M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMVT vs KURA

IMVT vs KURA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMVT vs. KURA commentary
Oct 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Hold and KURA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMVT with price predictions
Oct 16, 2026

IMVT in downward trend: 10-day moving average broke below 50-day moving average on September 10, 2026

The 10-day moving average for IMVT crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for IMVT entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +0.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 207 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

IMVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.407) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for KURA with price predictions
Oct 16, 2026

KURA in -7.55% downward trend, declining for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KURA declined for three days, in 256 of 313 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

KURA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KURA crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.

The Aroon Indicator for KURA entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.493) is normal, around the industry mean (26.823). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IMVT vs KURA: Fundamental Ratings
IMVT
KURA
OUTLOOK RATING
1..100
5250
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
63100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6375
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (51) in the null industry is in the same range as KURA (64) in the Biotechnology industry. This means that IMVT’s stock grew similarly to KURA’s over the last 12 months.

IMVT's Profit vs Risk Rating (63) in the null industry is somewhat better than the same rating for KURA (100) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than KURA’s over the last 12 months.

IMVT's SMR Rating (98) in the null industry is in the same range as KURA (99) in the Biotechnology industry. This means that IMVT’s stock grew similarly to KURA’s over the last 12 months.

IMVT's Price Growth Rating (63) in the null industry is in the same range as KURA (75) in the Biotechnology industry. This means that IMVT’s stock grew similarly to KURA’s over the last 12 months.

IMVT's P/E Growth Rating (100) in the null industry is in the same range as KURA (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTKURA
RSI
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 26 days ago
77%
Bullish Trend about 1 month ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
74%
COMPARISON
Comparison
Oct 18, 2026
Stock price -- (IMVT: $26.73 vs. KURA: $9.08)
Brand notoriety: IMVT and KURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 114% vs. KURA: 93%
Market capitalization -- IMVT: $6.92B vs. KURA: $943.87M
IMVT [@Biotechnology] is valued at $6.92B. KURA’s [@Biotechnology] market capitalization is $943.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green while KURA’s FA Score has 0 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • KURA’s FA Score: 0 green, 5 red.
According to our system of comparison, IMVT is a better buy in the long-term than KURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 3 TA indicator(s) are bullish while KURA’s TA Score has 4 bullish TA indicator(s).

  • IMVT’s TA Score: 3 bullish, 3 bearish.
  • KURA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both IMVT and KURA are a good buy in the short-term.

Price Growth

IMVT (@Biotechnology) experienced а -12.27% price change this week, while KURA (@Biotechnology) price change was -14.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

IMVT is expected to report earnings on Nov 18, 2026.

KURA is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMVT
Daily Signal:
Gain/Loss:
KURA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FXU46.860.76
+1.65%
First Trust Utilities AlphaDEX Fund (FXU)
RFCI21.64-0.03
-0.12%
ALPS Dynamic Core Income ETF (RFCI)
MOAT110.63-0.60
-0.54%
VanEck Morningstar Wide Moat ETF (MOAT)
GURU65.56-1.17
-1.75%
Global X Guru Index ETF (GURU)
WGMI31.29-3.42
-9.85%
CoinShares Bitcoin Mining and Digital Power ETF (WGMI)

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-2.84%
ROIV - IMVT
63%
Loosely correlated
-1.50%
KURA - IMVT
53%
Loosely correlated
-6.39%
NAMS - IMVT
45%
Loosely correlated
-3.83%
LXEO - IMVT
45%
Loosely correlated
-4.35%
DYN - IMVT
45%
Loosely correlated
-6.80%
More